Scarica l'app Stockscreener
16.60
32.23%
-7.85
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SRPT Giù?
Forum
Previsione
Frazionamento azionario
Sarepta Therapeutics Inc Borsa (SRPT) Ultime notizie
Baird Maintains Neutral Rating, Lowers Price Target on SRPT | SRPT Stock News - GuruFocus
SRPT Q3 Earnings Miss Estimates, Stock Dips on DMD Study Failure - Zacks Investment Research
Scandal and controversy take toll on FDA credibility - statnews.com
Sarepta (SRPT) Shares Plummet Over 33% - GuruFocus
Sarepta Faces Investor Skepticism As Duchenne Data Falls Short Of Statistical Significance - inkl
Sarepta (SRPT) Faces Stock Plunge Amid Clinical Trial Setbacks - GuruFocus
Sarepta stock plummets as confirmatory Duchenne trial fails - The Business Journals
Top Stock Movers Now: Palantir, Sarepta Therapeutics, Denny's, and More - MSN
Sarepta Stock Dumps: Pharma Bro Martin Shkreli Still Likes It - Benzinga
Sarepta Therapeutics Stock Tumbles After Trial Data - Schaeffer's Investment Research
Palantir, Uber, Sarepta, Tesla, Norwegian Cruise Line, Hertz, AMD, and More Movers - Barron's
Sarepta (SRPT) Stock Plummets Over 30% - GuruFocus
Sarepta shares tumble on trial failure, weak Elevidys outlook - Reuters
Sarepta Plunges On Study Failures, Gene Therapy Outlook - Investor's Business Daily
Stocks to Watch Tuesday: Palantir, Sarepta, Tesla -- WSJ - 富途牛牛
Sarepta Stock Dives 35% After Earnings Report. Why Shares Are Crashing. - Barron's
Sarepta Therapeutics (SRPT) Stock: Clinical Failure Triggers Massive Selloff - parameter.io
Sarepta Therapeutics (SRPT) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo! Finance UK
Sarepta Duchenne drugs come up short in confirmatory test - BioPharma Dive
Insperity Posts Downbeat Q3 Results, Joins IAC, Archer-Daniels-Midland And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
FDA Duchenne Failure Hits Sarepta Amid 3Q25 Earnings Beat (NASDAQ:SRPT) - Seeking Alpha
Sarepta’s DMD Exon-Skippers Fail Confirmatory Study, Stock Craters - BioSpace
Stocks making the biggest moves premarket: Uber, Sarepta, Palantir, Norwegian Cruise and more - CNBC
Sarepta shares slide as DMD treatment woes pile up - pharmaphorum
Needham Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating - 富途牛牛
Sarepta Says Older Muscle Disease Drugs Failed Confirmatory Trial - Bloomberg
Sarepta Earnings Beat Expectations. Why the Stock Is Down 40%. - Barron's
Sarepta slumps after approved muscle disorder drugs fail confirmatory trial - TradingView
Palantir, Sarepta, Tesla, Uber, Pfizer, Norwegian Cruise Line, Amazon, AMD, and More Movers - Barron's
Morning Market Movers: DENN, SRPT, JELD, ICHR See Big Swings - RTTNews
Sell Rating for Sarepta Therapeutics Amid ESSENCE Study Disappointment and Reimbursement Concerns - TipRanks
Sarepta slumps as trial failure deepens woes for drugmaker - Yahoo! Finance Canada
Two of Sarepta’s DMD drugs fail to meet primary endpoint in confirmatory trial - Yahoo Finance
Multi asset correlation models including Sarepta Therapeutics Inc.Weekly Stock Analysis & Community Consensus Picks - newser.com
Relative strength of Sarepta Therapeutics Inc. in sector analysisPortfolio Return Report & Long-Term Growth Plans - newser.com
Sarepta Stock Tumbles 40%. Why the Biotech’s Shares Are Sinking. - MSN
Dow Futures Edge Lower On Pullback Fears: PLTR, SRPT, TSLA, AMD Among Stocks To Watch - Stocktwits
Baird lowers Sarepta Therapeutics stock price target to $15 on ESSENCE trial failure - Investing.com Nigeria
Analyzing drawdowns of Sarepta Therapeutics Inc. with statistical toolsTrade Analysis Report & Risk Controlled Daily Trade Plans - newser.com
Palantir, Sarepta, Tesla, Amazon, AMD, Pfizer, and More Stock Market Movers - Barron's
Palantir, Sarepta, Amazon, AMD, Pfizer, and More Stock Market Movers - Barron's
Sarepta Therapeutics (SRPT) Stock Crashes as Nine-Year Trial Ends in Disappointment - CoinCentral
Biggest stock movers Tuesday: PLTR, SRPT, and more (NASDAQ:PLTR) - Seeking Alpha
Sarepta slumps as gene therapy setback adds to drug pipeline woes - Yahoo Finance
Pinnacle Associates Ltd. Has $997,000 Holdings in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Stocks to Watch Tuesday: Palantir, Sarepta, Tesla - The Wall Street Journal
Is Sarepta Therapeutics Inc. stock supported by strong cash flowsJuly 2025 Levels & Risk Managed Investment Signals - newser.com
Will Sarepta Therapeutics Inc. (AB3A) stock test record highs in 2025July 2025 Gainers & Consistent Income Trade Ideas - newser.com
Will Sarepta Therapeutics Inc. stock benefit from sector rotationQuarterly Market Review & Technical Confirmation Alerts - newser.com
Sarepta Therapeutics Swings to Q3 Adjusted Loss, Revenue Falls; Shares Down Pre-Bell - MarketScreener
What technical charts say about Sarepta Therapeutics Inc. stockJuly 2025 Macro Moves & High Accuracy Investment Signals - newser.com
What technical models suggest about Sarepta Therapeutics Inc.’s comeback - newser.com
Capricor Therapeutics Stock Becomes Talk Of Retail Town On DMD Study; Retail Sees New Hope After Sarepta Setback - Stocktwits
Sarepta Therapeutics (SRPT) to Join S&P SmallCap 600 - GuruFocus
Why Sarepta Therapeutics Shares Tumbled Today - TipRanks
Sarepta Stock’s (SRPT) Painful Plunge! Is There Any Hope Left for Investors after DMD Trial Miss? - TipRanks
Earnings Snapshot: Sarepta Q3 beat; ESSENCE study did not meet statistical significance on primary endpoint - MSN
Sarepta Therapeutics Inc (SRPT) Q3 2025 Earnings Call Highlights: Resilient Revenue Amidst ... - Yahoo Finance
Sarepta Therapeutics Stock Crashes After-Hours On DMD Trial Failure, Q3 Print — Retail Still Sees Long-Term Comeback - Stocktwits
Sarepta Therapeutics Reports Q3 2025 Financial Results - TipRanks
Transcript : Sarepta Therapeutics, Inc., Q3 2025 Earnings Call, Nov 03, 2025 - MarketScreener
Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE - BioSpace
Sarepta Therapeutics (SRPT): Assessing Valuation After Q3 Earnings Reveal Swing to Net Loss - simplywall.st
Sarepta's shares sink after antisense DMD therapies fail confirmatory trial - FirstWord Pharma
Sarepta Therapeutics: Q3 Earnings Snapshot - CTPost
Sarepta Therapeutics Outpaces Forecasts On Gene Therapy Strength - Finimize
Earnings call transcript: Sarepta Therapeutics beats Q3 2025 EPS forecast - Investing.com
1.13%
0.49%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):